These fourth-generation EGFR inhibitors are anticipated to serve as a lead compound for the development of new anticancer medicines against NSCLC cells resistant to second- and third-generation EGFR inhibitor drugs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.